PALATIN TECHNOLOGIES INCPTNEarnings & Financial Report
Palatin Technologies Inc. is a biopharmaceutical firm developing targeted receptor-specific therapeutic products for unmet medical needs across cardiovascular care, renal disease treatment, and sexual health segments. It serves patients and healthcare providers mainly in North American and global pharmaceutical markets.
Revenue
$1.8M
Gross Profit
$1.7M
Operating Profit
$-10.8M
Net Profit
$-9.8M
Gross Margin
94.1%
Operating Margin
-614.0%
Net Margin
-557.3%
YoY Growth
128.6%
PALATIN TECHNOLOGIES INC Q4 FY2023 Financial Summary
PALATIN TECHNOLOGIES INC reported revenue of $1.8M (up 128.6% YoY) for Q4 FY2023, with a net profit of $-9.8M (up 23.1% YoY) (-557.3% margin). Cost of goods sold was $104.0K, operating expenses totaled $12.5M.
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-9.8M |
| Gross Margin | 94.1% |
| Operating Margin | -614.0% |
| Report Period | Q4 FY2023 |
PALATIN TECHNOLOGIES INC Annual Revenue by Year
PALATIN TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2023 revenue was $4.9M).
| Year | Annual Revenue |
|---|---|
| 2023 | $4.9M |
| 2022 | $1.5M |
PALATIN TECHNOLOGIES INC Quarterly Revenue & Net Profit History
PALATIN TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $116.0K | +104.4% | $-7.3M | -6260.0% |
| Q1 FY2026 | $8.8M | — | $4.7M | 52.9% |
| Q3 FY2025 | $0 | — | $-4.8M | N/A |
| Q1 FY2025 | $0 | — | $-7.8M | N/A |
| Q3 FY2024 | $0 | — | $-8.4M | N/A |
| Q2 FY2024 | $2.0M | +98.2% | $-7.8M | -385.6% |
| Q1 FY2024 | $2.1M | +142.2% | $-5.2M | -247.2% |
| Q4 FY2023 | $1.8M | +128.6% | $-9.8M | -557.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $2.1M | $2.0M | $0 | $0 | $0 | $8.8M | $116036 |
| YoY Growth | 128.6% | 142.2% | 98.2% | N/A | N/A | N/A | N/A | 104.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $17.9M | $11.2M | $13.6M | $11.4M | $3.4M | $3.7M | $8.6M | $17.9M |
| Liabilities | $19.7M | $16.1M | $24.5M | $9.8M | $11.1M | $10.1M | $8.2M | $6.5M |
| Equity | $-2.0M | $-6.3M | $-11.4M | $1.6M | $-7.7M | $-6.4M | $396399 | $11.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.6M | $-5.9M | $-10.5M | $-8.6M | $-7.0M | $-5.4M | $-1.6M | $-4.8M |